App-Based Certified Diabetes Education Therapy (AB-CDE)

Part of paid clinical trials in La Jolla, California.

Sponsor
Oregon Health and Science University
Study ID
NCT07282639
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Type 1 Diabetes (T1D)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DailyDose — DEVICE
    Our team has developed a smartphone-based application, DailyDose Decision Support Tool (DailyDose), that combines continuous glucose monitoring data and insulin data to provide decision support for people living with T1D taking MDI. DailyDose is an iPhone application that is designed to support this population by 1) allowing for bolus calculation based on inputs including carbohydrate intake, CGM value and trend, and exercise information, 2) providing recommendations for carbohydrate intake based on exercise type, intensity, and duration, and 3) providing weekly recommendations for adjustments in insulin doses at specific times of day, including basal insulin dose, carbohydrate ratios or fixed mealtime doses, and correction factors .

Study Details

The purpose of this study is to learn more about a smartphone application (app) called DailyDose, an investigational decision support tool that may help in managing your diabetes. DailyDose tracks your continuous glucose monitoring (CGM) data, insulin use, and exercise, and uses this information to provide personalized recommendations for insulin dosing and carbohydrate intake during exercise or low blood sugar events. We want to find out if DailyDose can help lower blood sugar levels as measured by the hemoglobin A1c (HbA1c) test.

Key Dates

Start date
Jan 15, 2026
Status verified
Dec 2025
Primary completion
May 15, 2027
Completion
Dec 15, 2027

Study Design

Enrollment
99 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention Group
    AB-CDE intervention using DailyDose, study CGM, and CDE and BH counselling if indicated
  • No Intervention: Control Group
    Usual care including MDI insulin therapy with study CGM and DailyDose in Data-logging Mode.

Primary Outcome Measure

Change in hemoglobin A1c (HbA1c) from baseline to 24 weeks after randomization [ Time Frame: Enrollment and 24 weeks after randomization ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
University of California, San DiegoLa JollaCalifornia92037
Jeremy Pettus, MD
[email protected]
858-246-2169
Todd May
[email protected]
University of Southern CaliforniaLos AngelesCalifornia90022-
Barbara Davis CenterAuroraColorado80045
Halis Akturk, MD
[email protected]
303-724-0467
Emma Mason
[email protected]
303-724-5895
Joslin Diabetes Center, Harvard School of MedicineBostonMassachusetts02215
Joslin Toschi, MD
[email protected]
617-309-2440
Christine Slyne
[email protected]
Mount Sinai School of MedicineNew YorkNew York10029
Carol Levy, MD
[email protected]
212-241-0068
Shaziah Hassan
[email protected]
Oregon Health & Science University , PortlandPortlandOregon97239
Leah Wilson, MD
[email protected]
503-494-3273
Peter Jacobs, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in La Jolla, CA

By research site
University of California, San Diego· La Jolla, CAUniversity of Southern California· Los Angeles, CABarbara Davis Center· Aurora, COJoslin Diabetes Center, Harvard School of Medicine· Boston, MAMount Sinai School of Medicine· New York, NYOregon Health & Science University , Portland· Portland, OR

Related Studies